The startup develops and provides PidPort, an AI-powered cloud system that supports digital pathology
Medmain Inc, a Japanese medtech startup that offers PidPort, an artificial intelligence (AI)-powered cloud system to assist in digital pathology, has been selected for the “US Market Gateway Accelerator for BioSciences and MedTech”, an acceleration programme sponsored by WorldUpstart, LLC. The firm will take advantage of this opportunity to move forward with its business development in the US.
The “US Market Gateway Accelerator for BioSciences and MedTech”, sponsored by WorldUpstart, LLC, is an acceleration programme that provides medical tech and life sciences startups with a proven track record outside the US with the opportunity to enter and grow their business in the US market.
Through this programme, the startup will receive advice on business development in the US, ranging from FDA filings, marketing strategies for the US healthcare market, intellectual property strategies, financing and business alliance strategies, and promotional support, among others.
Medmain will introduce PidPort, the AI-powered cloud system designed to support digital pathology, at the upcoming “Philadelphia Alliance for Capital and Technology Conference”, the largest annual startup conference in Philadelphia, which will be held in November 2023.
The startup was selected this year to receive funding from the Japan Agency for Medical Research and Development (AMED), a funding agency that plays a central role in R&D in the Japanese medical field and the development of its infrastructure.
